Headshot of Daniel Geschwind.

Daniel Geschwind

Professor, University of California, Los Angeles;
Contributing editor, The Transmitter

Daniel Geschwind is Gordon and Virginia MacDonald Distinguished Professor of Neurology, Psychiatry and Human Genetics at the University of California, Los Angeles. As senior associate dean and associate vice chancellor of precision health, he leads the university’s Institute for Precision Health.

His lab has pioneered the application of systems biology methods in neurologic and psychiatric disease, with a focus on autism and neurodegenerative conditions. His lab has made major contributions to identifying genetic causes of autism, defining the molecular pathology of autism and allied psychiatric disorders, and has worked to increase diversity in autism research. His work in dementia focuses on the mechanisms of tauopathies, where his lab is developing novel therapeutic approaches.

Geschwind sits on the editorial boards of Cell, Science and Neuron, and he is among the highest cited neurologists in the world. He has received several awards for his lab’s work, including the American Neurological Association’s Derek Denny-Brown Neurological Scholar Award, and most recently the Society of Biological Psychiatry Gold Medal Award and the American Academy of Neurology’s 2022 Cotzias Lecture and Award. He is the 2022 National Academy of Medicine recipient of the Rhoda and Bernard Sarnat International Prize in Mental Health. He is an elected member of the American Association of Physicians and the National Academy of Medicine.

Explore more from The Transmitter

Headshots of Yale researchers Yong-Hui Jiang and Jiangbing Zhou.

Supported by a $40 million NIH grant, Yale brain shuttle technology raises questions

Yale University claims its STEP platform might be able to deliver gene-editing tools into the brain via multiple routes. Researchers are eager to see more.

By Natalia Mesa
3 June 2026 | 11 min read

What counts as a ‘naturalistic’ behavior?

Nedah Nemati explains how neuroscience methods and the lived experience of the scientists themselves shape how we define the behaviors we seek to explain.

By Paul Middlebrooks
3 June 2026 | 1 min read
Research image of brain cells involved with Amyotrophic lateral sclerosis (ALS) illuminated through genetic tools

Allen Institute sets sights on treatments for five brain diseases

The Brain Health Accelerator program aims to harness single-cell transcriptomics and cell-type-specific genetic tools to develop treatments for Alzheimer’s, Huntington’s and Parkinson’s diseases, Lewy body dementia and ALS.

By Calli McMurray
2 June 2026 | 5 min read